The FDA has approved imlunestrant with abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. The decision adds another precision-treatment option guided by a tumour mutation that can be detected in circulating tumour DNA.
The FDA has expanded finerenone treatment to adults with chronic kidney disease associated with type 1 diabetes, following a Phase 3 trial showing a significant reduction in urinary albumin. The approval provides a new kidney-directed treatment option, but the trial did not directly prove that finerenone prevents kidney failure or dialysis in this population.
An international prospective study involving 1,785 people found that a blood-based test combining a microRNA signature with the established marker CA19-9 detected about 87% of stage I–II pancreatic cancers. The result is promising for earlier detection, but PANXEON is not yet an established screening test and needs larger prospective studies before routine clinical use.
A first-in-disease Phase 1 trial found deep B-cell depletion and encouraging remission signals after treatment with the experimental bispecific antibody A-319 in people with active lupus. The approach could eventually offer a simpler alternative to individualized CAR-T therapy, but the study involved only 12 patients and cannot yet establish effectiveness.
A randomized Phase 2 trial found much deeper responses with teclistamab than with lenalidomide–dexamethasone in people with high-risk smoldering multiple myeloma. The findings raise the possibility of treating dangerous precursor disease earlier, but the trial was small and does not yet show that overt myeloma or death can be prevented.
The FDA has approved apitegromab as the first spinal muscular atrophy treatment designed to act directly on muscle loss. It is used alongside existing SMN-targeted therapy rather than replacing it, adding a new treatment strategy for people who can remain weak despite major advances in SMA care.
A randomized trial involving nearly 1,000 people with ischemic stroke found better recovery after treatment with the experimental drug loberamisal, including when treatment began many hours after the stroke. The finding is promising, but further trials are needed before the drug can become established treatment.
The FDA has expanded approval of sevabertinib so that some people with advanced HER2-mutated lung cancer can receive the targeted treatment before other systemic therapy, marking another step toward treatment based on a tumor’s genetic changes.
An experimental inhaled RNA medicine successfully reduced a selected inflammatory protein inside the lungs in an early human trial, suggesting that gene-silencing medicines may eventually be delivered directly to lung tissue.
A randomized study found major pain relief and improved sensation in people with severe painful diabetic neuropathy treated with high-frequency spinal-cord stimulation, while preliminary tissue findings raised questions about whether nerve changes may extend beyond pain control.
A randomized trial involving nearly 1,700 people found no statistically significant reduction in COPD exacerbations, cardiovascular events or death when metoprolol was added in patients who had no cardiovascular indication for the drug.
An AI system analysing ordinary carotid ultrasound images identified potentially vulnerable artery plaques and separated people into groups with substantially different subsequent stroke-related risk.
The FDA has approved rebisufligene etisparvovec-hopf, a one-time gene therapy for eligible children with Sanfilippo syndrome type A, marking the first approved treatment for this rare inherited neurodegenerative disease. The evidence suggests better preservation of cognitive development than seen in an untreated natural-history group, but the pivotal comparison was not a conventional randomized placebo-controlled trial.
A first-in-disease Phase 1 trial found deep B-cell depletion and encouraging remission signals after treatment with the experimental bispecific antibody A-319 in people with active lupus. The approach could eventually offer a simpler alternative to individualized CAR-T therapy, but the study involved only 12 patients and cannot yet establish effectiveness.
An experimental inhaled RNA medicine successfully reduced a selected inflammatory protein inside the lungs in an early human trial, suggesting that gene-silencing medicines may eventually be delivered directly to lung tissue.
A genetically modified pig kidney worked for 271 days in a man with kidney failure, allowing him to avoid dialysis before he later received a human donor kidney.
U.S. regulators approved Casgevy in December 2023 — the world's first medicine based on CRISPR-Cas9 gene editing — offering a potential one-time functional cure for sickle cell disease and marking a watershed moment in the history of genetic medicine.
The FDA has approved levacetylleucine for ataxia associated with ataxia-telangiectasia, creating the first approved treatment specifically for this neurological feature of the rare inherited disease. A randomized Phase 3 trial found improved ataxia scores over 12 weeks, but whether the treatment changes long-term neurodegeneration remains unknown.
The FDA has approved imlunestrant with abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. The decision adds another precision-treatment option guided by a tumour mutation that can be detected in circulating tumour DNA.
The FDA has expanded finerenone treatment to adults with chronic kidney disease associated with type 1 diabetes, following a Phase 3 trial showing a significant reduction in urinary albumin. The approval provides a new kidney-directed treatment option, but the trial did not directly prove that finerenone prevents kidney failure or dialysis in this population.
The FDA has approved apitegromab as the first spinal muscular atrophy treatment designed to act directly on muscle loss. It is used alongside existing SMN-targeted therapy rather than replacing it, adding a new treatment strategy for people who can remain weak despite major advances in SMA care.
Mpox (වඳුරු උණ) වෛරසයේ ව්යාප්තිය පිළිබඳව ශ්රී ලංකා සෞඛ්ය අංශ සහ ලෝක සෞඛ්ය සංවිධානය (WHO) දැඩි අවධානයෙන් පසුවේ. අප්රේල් 13 වන දින වන විට, මෙරට තුළ වෛරසය පැතිරීමේ ක්ෂණික තර්ජනයක් නොමැති වුවද, ජාත්යන්තර සංචාරකයින් හරහා සිදුවිය හැකි ආසාදනය වීම් වළක්වා ගැනීමට පියවර ගෙන ඇත.
ස්ථූලතාවයට එරෙහිව සටන් කළ හැකි නවතම විද්යාත්මක සොයාගැනීමක් ලෙස, මොළයේ ඇති 'Astrocytes' නම් තාරකා හැඩැති සෛල මගින් ආහාර රුචිය පාලනය කරන ආකාරය පර්යේෂකයන් විසින් සොයාගෙන ඇත. මෙය ඉදිරියේදී අතුරු ආබාධවලින් තොර බර අඩු කිරීමේ ඖෂධ නිපදවීමට විශාල පිටුවහලක් වනු ඇතැයි අපේක්ෂා කෙරේ.
The World Health Organization declared mpox a public health emergency of international concern in August 2024 — its second such declaration in two years — as a new, more transmissible clade Ib strain spread rapidly through the Democratic Republic of Congo and neighbouring countries.
